Development of AVID200, a novel TGF-β targeting immunotherapy: characterization of immunomodulatory effects

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1016/S0959-8049(16)32910-0
AuthorSearch for: ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: 1 ; Search for: ; Search for: 1 ; Search for: ; Search for:
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Journal titleEuropean Journal of Cancer
ISSN0959-8049
Volume69
PagesS105
Abstract
Publication date
Note28 EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics Wednesday 29 November 2016: Poster Sessions: Immunotherapy: Poster (Board P144)
LanguageEnglish
Peer reviewedYes
NPARC number23001208
Export citationExport as RIS
Report a correctionReport a correction
Record identifierfc21b4ce-4778-42e5-9a89-dade828fc71b
Record created2017-01-05
Record modified2017-01-05
Date modified: